GEHC) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts

GE HealthCare Technologies Inc. (NASDAQ:GEHC) shareholders are probably feeling a little disappointed, since its shares fell 4.1% to US$74.95 in the week after its latest third-quarter results. It looks like the results were a bit of a negative overall. While revenues of US$5.1b were in line with analyst predictions, statutory earnings were less than expected, missing estimates by 2.2% to hit US$0.98 per share. Earnings are an important time for investors, as they can track a company’s performance, look at what the analysts are forecasting for next year, and see if there’s been a change in sentiment towards the company. Readers will be glad to know we’ve aggregated the latest statutory forecasts to see whether the analysts have changed their mind on GE HealthCare Technologies after the latest results.

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

Taking into account the latest results, the most recent consensus for GE HealthCare Technologies from 18 analysts is for revenues of US$21.4b in 2026. If met, it would imply a reasonable 5.8% increase on its revenue over the past 12 months. Statutory earnings per share are expected to dip 3.4% to US$4.70 in the same period. Yet prior to the latest earnings, the analysts had been anticipated revenues of US$21.4b and earnings per share (EPS) of US$4.68 in 2026. The consensus analysts don’t seem to have seen anything in these results that would have changed their view on the business, given there’s been no major change to their estimates.

Check out our latest analysis for GE HealthCare Technologies

The analysts reconfirmed their price target of US$88.44, showing that the business is executing well and in line with expectations. That’s not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. There are some variant perceptions on GE HealthCare Technologies, with the most bullish analyst valuing it at US$108 and the most bearish at US$73.00 per share. This shows there is still a bit of diversity in estimates, but analysts don’t appear to be totally split on the stock as though it might be a success or failure situation.

These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the GE HealthCare Technologies’ past performance and to peers in the same industry. The analysts are definitely expecting GE HealthCare Technologies’ growth to accelerate, with the forecast 4.6% annualised growth to the end of 2026 ranking favourably alongside historical growth of 3.7% per annum over the past five years. Compare this with other companies in the same industry, which are forecast to see revenue growth of 8.4% annually. It seems obvious that, while the future growth outlook is brighter than the recent past, GE HealthCare Technologies is expected to grow slower than the wider industry.

The most important thing to take away is that there’s been no major change in sentiment, with the analysts reconfirming that the business is performing in line with their previous earnings per share estimates. On the plus side, there were no major changes to revenue estimates; although forecasts imply they will perform worse than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.

With that said, the long-term trajectory of the company’s earnings is a lot more important than next year. We have estimates – from multiple GE HealthCare Technologies analysts – going out to 2027, and you can see them free on our platform here.

However, before you get too enthused, we’ve discovered 1 warning sign for GE HealthCare Technologies that you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.